Clinical Trials Browser

Not yet recruiting × Interventional × Nivolumab × Clear all

NCT07176975 2026-05-26

A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers

Phase 1 Not yet recruiting

Other solid neoplasm

Solid Tumors

NCT07355205 2026-05-22

FLINN

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07603856 2026-05-22

REVIVE

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07551583 2026-05-20

Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL

Phase 2 Not yet recruiting

Hodgkin Disease

NCT07541170 2026-05-15

KRASCENDO 3

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07576725 2026-05-08

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

Phase 2 Not yet recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Clear-cell metastatic renal cell carcinoma, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Hodgkin Disease, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Kaposi, Colorectal Neoplasms, Carcinoma, Merkel Cell

NCT07430202 2026-05-06

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Phase 1 Not yet recruiting

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

NCT07420439 2026-04-27

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

Phase 2 Not yet recruiting

Lung Diseases, Interstitial

NCT07518043 2026-04-15

A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors

Phase 1 Not yet recruiting

DermatologicGenitourinary

Carcinoma, Transitional Cell, Melanoma

NCT07527858 2026-04-14

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Advanced Microsatellite Stable Colorectal Cancer

NCT07529873 2026-04-14

N'FORCE

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07514767 2026-04-07

NOCANO

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07476326 2026-04-03

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

Phase 1 Not yet recruiting

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasms

NCT07510334 2026-04-03

VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Phase 2 Not yet recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT07501117 2026-03-30

Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma

Phase 1 Not yet recruiting

Uveal Melanoma

NCT07494435 2026-03-27

Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT07492680 2026-03-25

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Phase 2 Not yet recruiting

CNSDermatologicGastrointestinal

Brain Neoplasms, Melanoma, Pancreatic Neoplasms

NCT06639607 2026-03-10

PRiME II

Phase 1/2 Not yet recruiting

Diffuse Intrinsic Pontine Glioma, Ependymoma, Medulloblastoma, Recurrence

NCT07460765 2026-03-10

Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 1 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms, Squamous Cell

NCT07459543 2026-03-09

A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India

Phase 4 Not yet recruiting

Melanoma, Skin Neoplasms

NCT07444619 2026-03-03

A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

Phase 1 Not yet recruiting

Sarcoma

NCT07403877 2026-02-11

TORCH-OPTIMA

Phase 2 Not yet recruiting

Gastrointestinal

Turcot syndrome, Colorectal Neoplasms

NCT07404332 2026-02-11

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

Phase 1 Not yet recruiting

Neoplasm Metastasis

NCT07383441 2026-02-03

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

Phase 3 Not yet recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT07369791 2026-01-28

NOBLE

Phase 2 Not yet recruiting

Gastrointestinal

Advanced Biliary Tract Cancer(BTC)

NCT07338981 2026-01-14

The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.

Phase 3 Not yet recruiting

Advanced Kidney Cancer

NCT07233668 2025-12-03

IVE in mRCC

Phase NA Not yet recruiting

Carcinoma, Renal Cell

NCT07216833 2025-10-15

Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 1 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07187869 2025-09-23

Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study

Phase 1 Not yet recruiting

Carcinoma, Renal Cell

NCT06692491 2024-11-18

SPRING

Phase 2 Not yet recruiting

Rare Tumour

NCT06683755 2024-11-12

Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)

Phase 1/2 Not yet recruiting

Melanoma

NCT05597800 2022-10-28

LUNGVIR

Phase 2 Not yet recruiting

Post-Acute COVID-19 Syndrome, Carcinoma, Non-Small-Cell Lung